There have been multiple approaches aimed at slowing down the degenerative processes, but they have primarily focused on inhibiting the formation or promoting the removal of toxic forms of amyloid beta (Aβ) peptide or tau (for AD) or α-synuclein (for PD) (Brundin et al., 2017; Jan et al., 2017). This evidence concerns the gene MAPT and Alzheimer disease.